Comparison of univariate and multivariate analyses for brain [18F]FDG PET data in α-synucleinopathies
- PMID: 37494757
- PMCID: PMC10394024
- DOI: 10.1016/j.nicl.2023.103475
Comparison of univariate and multivariate analyses for brain [18F]FDG PET data in α-synucleinopathies
Abstract
Background: Brain imaging with [18F]FDG-PET can support the diagnostic work-up of patients with α-synucleinopathies. Validated data analysis approaches are necessary to evaluate disease-specific brain metabolism patterns in neurodegenerative disorders. This study compared the univariate Statistical Parametric Mapping (SPM) single-subject procedure and the multivariate Scaled Subprofile Model/Principal Component Analysis (SSM/PCA) in a cohort of patients with α-synucleinopathies.
Methods: We included [18F]FDG-PET scans of 122 subjects within the α-synucleinopathy spectrum: Parkinson's Disease (PD) normal cognition on long-term follow-up (PD - low risk to dementia (LDR); n = 28), PD who developed dementia on clinical follow-up (PD - high risk of dementia (HDR); n = 16), Dementia with Lewy Bodies (DLB; n = 67), and Multiple System Atrophy (MSA; n = 11). We also included [18F]FDG-PET scans of isolated REM sleep behaviour disorder (iRBD; n = 51) subjects with a high risk of developing a manifest α-synucleinopathy. Each [18F]FDG-PET scan was compared with 112 healthy controls using SPM procedures. In the SSM/PCA approach, we computed the individual scores of previously identified patterns for PD, DLB, and MSA: PD-related patterns (PDRP), DLBRP, and MSARP. We used ROC curves to compare the diagnostic performances of SPM t-maps (visual rating) and SSM/PCA individual pattern scores in identifying each clinical condition across the spectrum. Specifically, we used the clinical diagnoses ("gold standard") as our reference in ROC curves to evaluate the accuracy of the two methods. Experts in movement disorders and dementia made all the diagnoses according to the current clinical criteria of each disease (PD, DLB and MSA).
Results: The visual rating of SPM t-maps showed higher performance (AUC: 0.995, specificity: 0.989, sensitivity 1.000) than PDRP z-scores (AUC: 0.818, specificity: 0.734, sensitivity 1.000) in differentiating PD-LDR from other α-synucleinopathies (PD-HDR, DLB and MSA). This result was mainly driven by the ability of SPM t-maps to reveal the limited or absent brain hypometabolism characteristics of PD-LDR. Both SPM t-maps visual rating and SSM/PCA z-scores showed high performance in identifying DLB (DLBRP = AUC: 0.909, specificity: 0.873, sensitivity 0.866; SPM t-maps = AUC: 0.892, specificity: 0.872, sensitivity 0.910) and MSA (MSARP: AUC: 0.921, specificity: 0.811, sensitivity 1.000; SPM t-maps: AUC: 1.000, specificity: 1.000, sensitivity 1.000) from other α-synucleinopathies. PD-HDR and DLB were comparable for the brain hypo and hypermetabolism patterns, thus not allowing differentiation by SPM t-maps or SSM/PCA. Of note, we found a gradual increase of PDRP and DLBRP expression in the continuum from iRBD to PD-HDR and DLB, where the DLB patients had the highest scores. SSM/PCA could differentiate iRBD from DLB, reflecting specifically the differences in disease staging and severity (AUC: 0.938, specificity: 0.821, sensitivity 0.941).
Conclusions: SPM-single subject maps and SSM/PCA are both valid methods in supporting diagnosis within the α-synucleinopathy spectrum, with different strengths and pitfalls. The former reveals dysfunctional brain topographies at the individual level with high accuracy for all the specific subtype patterns, and particularly also the normal maps; the latter provides a reliable quantification, independent from the rater experience, particularly in tracking the disease severity and staging. Thus, our findings suggest that differences in data analysis approaches exist and should be considered in clinical settings. However, combining both methods might offer the best diagnostic performance.
Keywords: Imaging biomarkers; SSM/PCA; Univariate analyses; [18F]FDG-PET; α-synucleinopathies.
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures




Similar articles
-
Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and α-synuclein-related neurodegenerative disorders: A brain [18F]FDG PET study.Parkinsonism Relat Disord. 2019 Jul;64:97-105. doi: 10.1016/j.parkreldis.2019.03.017. Epub 2019 Mar 23. Parkinsonism Relat Disord. 2019. PMID: 30930059
-
Metabolic brain pattern in dementia with Lewy bodies: Relationship to Alzheimer's disease topography.Neuroimage Clin. 2022;35:103080. doi: 10.1016/j.nicl.2022.103080. Epub 2022 Jun 8. Neuroimage Clin. 2022. PMID: 35709556 Free PMC article.
-
Brain glucose metabolism in Lewy body dementia: implications for diagnostic criteria.Alzheimers Res Ther. 2019 Feb 23;11(1):20. doi: 10.1186/s13195-019-0473-4. Alzheimers Res Ther. 2019. PMID: 30797240 Free PMC article.
-
Orexin and Sleep Disturbances in Alpha-Synucleinopathies: a Systematic Review.Curr Neurol Neurosci Rep. 2024 Sep;24(9):389-412. doi: 10.1007/s11910-024-01359-6. Epub 2024 Jul 20. Curr Neurol Neurosci Rep. 2024. PMID: 39031323 Free PMC article.
-
Recent advances in establishing fluid biomarkers for the diagnosis and differentiation of alpha-synucleinopathies - a mini review.Clin Auton Res. 2022 Aug;32(4):291-297. doi: 10.1007/s10286-022-00882-1. Epub 2022 Jul 27. Clin Auton Res. 2022. PMID: 35895157 Free PMC article. Review.
Cited by
-
Progression trajectories from prodromal to overt synucleinopathies: a longitudinal, multicentric brain [18F]FDG-PET study.NPJ Parkinsons Dis. 2024 Oct 25;10(1):200. doi: 10.1038/s41531-024-00813-z. NPJ Parkinsons Dis. 2024. PMID: 39448609 Free PMC article.
-
IRMA: Machine learning-based harmonization of F-FDG PET brain scans in multi-center studies.Eur J Nucl Med Mol Imaging. 2025 Jul;52(8):2941-2958. doi: 10.1007/s00259-025-07114-4. Epub 2025 Feb 18. Eur J Nucl Med Mol Imaging. 2025. PMID: 39964544 Free PMC article.
-
The novel imaging methods in diagnosis and assessment of cerebrovascular diseases: an overview.Front Med (Lausanne). 2024 Apr 10;11:1269742. doi: 10.3389/fmed.2024.1269742. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38660416 Free PMC article. Review.
-
Whole-brain glucose metabolic pattern differentiates minimally conscious state from unresponsive wakefulness syndrome.CNS Neurosci Ther. 2024 Jun;30(6):e14787. doi: 10.1111/cns.14787. CNS Neurosci Ther. 2024. PMID: 38894559 Free PMC article.
-
Molecular imaging based spatiotemporal dynamics progression of brain glucose metabolism in multiple system atrophy.Eur J Nucl Med Mol Imaging. 2025 Aug 27. doi: 10.1007/s00259-025-07509-3. Online ahead of print. Eur J Nucl Med Mol Imaging. 2025. PMID: 40859026
References
-
- Alafuzoff, I., Hartikainen, P., 2018. Alpha-synucleinopathies. Handb Clin Neurol. 145. 339–353. - PubMed
-
- American Academy of Sleep Medicine, 2014. The international classification of sleep disorders (ICSD-3), American Academy of Sleep Medicine.
-
- Armstrong, M.J., Emre, M., 2020. Dementia with Lewy bodies and Parkinson disease dementia: More different than similar? Neurology. - PubMed
-
- Arnaldi D., Meles S.K., Giuliani A., Morbelli S., Renken R.J., Janzen A., Mayer G., Jonsson C., Oertel W.H., Nobili F., Leenders K.L., Pagani M. Brain Glucose Metabolism Heterogeneity in Idiopathic REM Sleep Behavior Disorder and in Parkinson’s Disease. J Parkinsons Dis. 2019;9(1):229–239. - PubMed
Further reading
-
- Cerami C., Dodich A., Greco L., Iannaccone S., Magnani G., Marcone A., Pelagallo E., Santangelo R., Cappa S.F., Perani D., Bastin C. The role of single-subject brain metabolic patterns in the early differential diagnosis of primary progressive aphasias and in prediction of progression to dementia. Journal of Alzheimer’s Disease. 2016;55(1):183–197. - PMC - PubMed